Formulation development of a biphasic release tablet-in-tablet system containing ketorolac tromethamine
PLOS One · 29.07.2026 · 21 (7) · e0354689
DOI: 10.1371/journal.pone.0354689 ↗Kurz gefasst
Fachartikel in der Zeitschrift PLOS One, online erschienen am 29.07.2026. Verfasst von Ping Zou und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacy, The Central Hospital of Wuhan, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China. Hauptthemen laut MEDLINE: Ketorolac Tromethamine, Tablets, Anti-Inflammatory Agents, Non-Steroidal. Die Arbeit nennt 32 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Chutian Elite Program of Hubei Province for Health Professionals.
Abstract (Originalsprache)
Ketorolac tromethamine (KT) is a potent nonsteroidal anti-inflammatory drug (NSAID) used for moderate to severe pain management. Its short elimination half-life necessitates frequent dosing, which can reduce patient compliance. The objective of this study was to formulate, develop, and optimize a novel biphasic-release tablet-in-tablet (TIT) system for KT to provide immediate pain relief followed by extended drug release. A TIT system was designed, comprising an immediate-release (IR) outer layer and an extended-release (ER) core matrix. The ER core was optimized using a 3 2 full factorial design, with the amounts of HPMC K100M and HPMC K4M as independent variables. Formulations were evaluated for pre- and post-compression parameters, drug-excipient compatibility, and in vitro drug release. The drug release kinetics and mechanism were analyzed using various mathematical models. The optimal ER core formulation (F1) exhibited a drug release of 4.6% at 0.5 h and 66.1% at 12 h, closely matching the theoretical profile (similarity factor f 2 = 51). Release kinetics followed the first-order model and the Korsmeyer-Peppas model indicated an anomalous (non-Fickian) release mechanism (n = 0.831). The corresponding TIT formulation (F11) demonstrated desired physicochemical properties: hardness of 75 N, friability of 0.59%, and rapid outer layer disintegration (
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Pharmacy, The Central Hospital of Wuhan, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.
- Key Laboratory for Molecular Diagnosis of Hubei Province, The Central Hospital of Wuhan, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, China.
- Department of Pharmacy, General Hospital of Central Theater Command, Wuhan, China.
- College of Nursing and Health Management & College of Life Science and Chemistry, Wuhan Donghu University, Wuhan, China.
- Department of Stomatology, General Hospital of Central Theater Command, Wuhan, China.
- Department of Clinical Pharmacy, General Hospital of Central Theater Command, Wuhan, China.
ORCID-Profile: Xiang-Yang Xie
Förderung
- Chutian Elite Program of Hubei Province for Health Professionals
Zitieren
APA
Zou, P., Zeng, Y., Liao, X. R., Xie, X. Y., Li, Y. K., Ma, Y. H., & Liu, H. (2026). Formulation development of a biphasic release tablet-in-tablet system containing ketorolac tromethamine. PLOS One, 21(7), e0354689. https://doi.org/10.1371/journal.pone.0354689
Vancouver
Zou P, Zeng Y, Liao XR, Xie XY, Li YK, Ma YH, et al. Formulation development of a biphasic release tablet-in-tablet system containing ketorolac tromethamine. PLOS One. 2026;21(7):e0354689. doi:10.1371/journal.pone.0354689
BibTeX
@article{Zou2026,
author = {Zou, Ping and Zeng, Yuan and Liao, Xiang-Ru and Xie, Xiang-Yang and Li, Yin-Ke and Ma, Yi-Hui and Liu, Hui},
title = {Formulation development of a biphasic release tablet-in-tablet system containing ketorolac tromethamine},
journal = {PLOS One},
year = {2026},
volume = {21},
number = {7},
pages = {e0354689},
doi = {10.1371/journal.pone.0354689}
}
EUVIMED